Last reviewed · How we verify
NCT05797649
Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)
trial in Pleural Effusion in 120 participants. Currently enrolling.
30 November 2025
Quick facts
| Lead sponsor | Chinese University of Hong Kong |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 July 2023 |
| Primary completion | 30 November 2025 |
| Estimated completion | 30 November 2025 |
| Sites | 1 location across Hong Kong |
Conditions studied
- Pleural Effusion — all drugs for Pleural Effusion →
- Heart Failure — all drugs for Heart Failure →
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
- Fluid Overload — all drugs for Fluid Overload →
Sponsor
Chinese University of Hong Kong
Who can join
18 and older, any sex, with Pleural Effusion or Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cardiac related pleural effusions: a narrative review.
Wijayaratne T, Yousuf A, Panchal R. · · 2024 · cited 9× · PMID 38505011 · DOI 10.21037/jtd-23-1731
Verify or expand the search:
- PubMed search for NCT05797649
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pleural Effusion
Currently open trials in the same condition.
- NCT07248774 — Effect of Bubble Positive Expiratory Pressure and Segmental Breathing Versus Incentive Spirometry in Pleural Effusion · NA · recruiting
- NCT07012759 — Pleural Effusion Biomarkers in Lung Adenocarcinoma Patients · recruiting
- NCT06958848 — 16F vs 24F Chest Drain After Minimally Invasive Lobectomy and/or Segmentectomy · NA · recruiting
- NCT06892691 — Pleuroscopy First Versus Thoracentesis First in Patients With Suspected Malignant Pleural Effusions · NA · recruiting
- NCT06314620 — Normal Saline Flushing With And Without Heparin Lock In Maintaining Small Bore Intercostal Chest Catheter (ICC) Patency · NA · recruiting
Other Chinese University of Hong Kong trials
Trials by the same sponsor.
- NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
- NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
- NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
- NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
- NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05797649 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
- Last refreshed: 13 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05797649.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing